Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Baidu
Novartis (NVS) shares dropped 12.7% to $139.56 in pre-market trading after its pelacarsen phase III trial missed the primary endpoint. Ionis Pharmaceuticals (IONS) fell 11.5% to $51.40 due to association with Novartis. Other stocks moving lower include Dyne Therapeutics (DYN), Sarepta Therapeutics (SRPT), and Baidu (BIDU).
How this was made
The 30-second read
Why it matters
The trial miss is the primary catalyst for the sharp decline in Novartis and related stocks.
Market read
First report of a major Phase III failure causing double‑digit pre‑market drops in large‑cap biotech stocks.
What to watch
Potential upcoming data from other partners or alternative indications could mitigate the impact.
Background
Pre‑market futures were down, with the Dow futures falling over 400 points.
Ticker impact
Novartis shares fell 12.7% in pre‑market after the pelacarsen Phase III trial missed its primary endpoint.
Further downside risk if additional data are negative; potential rebound if mitigation steps are announced.
Large‑cap biotech failure often triggers sustained sell‑off; market may price in additional risk.
Ionis shares declined 11.5% in pre‑market, mirroring Novartis's drop after the pelacarsen trial miss.
Likely short‑term pressure; watch for any partner updates.
Sympathy move without direct data; price may stabilize if partner clarifies path forward.
Market effects
Biotech sector may see broader risk aversion after trial failure.
European and US biotech stocks could face pressure.
Large‑cap pharma move influences global market sentiment.
Counterpoint
If the trial miss is limited to a specific endpoint, the long‑term value of pelacarsen may remain intact.
Key entities
- CompanyNovartis AG
Swiss pharma giant reporting trial failure.
- CompanyIonis Pharmaceuticals
Partner in pelacarsen development.
